Trial reportThe European respiratory journal2021
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
Trial report in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 6 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy.Diabetes, obesity & metabolism · 2026Pooled it
- Non-Pharmacological Interventions for Cough in Patients With Lung Cancer: A Systematic Review and Meta-Analysis.Journal of clinical nursing · 2026Pooled it
- Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough: a systematic review and dose-response meta-analysis of randomized controlled trials.Purinergic signalling · 2026Pooled it
- Cough monitoring systems in adults with chronic respiratory diseases: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Pooled it
- Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial.BMC medicine · 2026Trial
- Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers.International journal of molecular sciences · 2025Trial
- P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants.Clinical pharmacokinetics · 2024Trial
- Trial
- Cough desensitization treatment for patients with refractory chronic cough: results of a second pilot randomized control trial.BMC pulmonary medicine · 2023Trial
- The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial.Respiratory research · 2023Trial
- Trial
- First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.British journal of clinical pharmacology · 2022Trial
- Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.Clinical pharmacokinetics · 2022Trial
- Randomised trial of the P2XThe European respiratory journal · 2022Trial
- Physiological mechanisms and therapeutic targets in chronic cough.Physiological reports · 2026Review
- Structure of the human P2X3 receptor reveals the basis for subtype-selective inhibition by sivopixant.PLoS biology · 2026Article
- Beyond codeine - the evidence landscape of conventional, natural, and emerging antitussive therapies: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Article
- Unraveling the neuro-immune axis in cough hypersensitivity: from pathogenesis to synergistic management.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundATP acting
methodsIn period A, patients received placebo for 2 weeks then eliapixant 10 mg for 1 week. In period B, patients received eliapixant 50, 200 and 750 mg twice daily for 1 week per dose level. Patients were randomised 1:1 to period A-B (n=20) or B-A (n=20). The primary efficacy end-point was change in cough frequency assessed over 24 h. The primary safety end-point was frequency and severity of adverse events (AEs).
results37 patients completed randomised therapy. Mean cough frequency fell by 17.4%
conclusionsSelective P2X3 antagonism with eliapixant significantly reduced cough frequency and severity, confirming this as a viable therapeutic pathway for RCC. Taste-related side-effects were lower at therapeutic doses than with the less selective P2X3 antagonist gefapixant. Selective P2X3 antagonism appears to be a novel therapeutic approach for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.